Bedard, P. L., Jhaveri, K. L., Accordino, M. K., Cervantes, P. A., Gambardella, V., Hamilton, E., Italiano, P. A., Kalinsky, P. K., Krop, P. I. E., Oliveira, M., Schmid, P. P., Saura, C., Turner, P. N., Varga, A., Cheeti, S., Dey, A., Hilz, S., Hutchinson, K. E., Jin, Y., … Juric, D. (2025). Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. European Journal of Cancer, 221, 115397. https://doi.org/10.1016/j.ejca.2025.115397

Patel, S. H., Colby, S., Sohal, D., Guthrie, K. A., Kachnic, L. A., Chiorean, E. G., Lowy, A. M., Rocha, F. G., Hochster, H. S., Philip, P. A., & Ahmad, S. A. (2025). Chemotherapy dose density is prognostic for overall survival in patients with resectable pancreas cancer: A landmark analysis of SWOG 1505. Cancer, 131(4). Portico. https://doi.org/10.1002/cncr.35759

Krishnamurthy, A., Wang, H., Rhee, J. C., Davar, D., Moy, R. H., Ratner, L., Christner, S. M., Holleran, J. L., Deppas, J., Sclafani, C., Schmitz, J. C., Gore, S., Chu, E., Bakkenist, C. J., Beumer, J. H., & Villaruz, L. C. (2025). Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406). Cancer Chemotherapy and Pharmacology, 95(1). https://doi.org/10.1007/s00280-024-04745-6

Henick, B. S., Koch, P. D., Gainor, J. F., Awad, M. M., Chiuzan, C., Izard, S., Georgis, Y., Mallick, S., Garofano, R. F., Wong, C. V., Saqi, A., Grindheim, J., Schulze, K., Sonett, J. R., Rizvi, N. A., Izar, B., Taylor, A. M., & Shu, C. A. (2024). Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings. Journal for ImmunoTherapy of Cancer, 12(12), e009301. https://doi.org/10.1136/jitc-2024-009301

Jhaveri, K. L., Accordino, M. K., Bedard, P. L., Cervantes, A., Gambardella, V., Hamilton, E., Italiano, A., Kalinsky, K., Krop, I. E., Oliveira, M., Schmid, P., Saura, C., Turner, N. C., Varga, A., Cheeti, S., Hilz, S., Hutchinson, K. E., Jin, Y., Royer-Joo, S., … Juric, D. (2024). Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology, 42(33), 3947–3956. https://doi.org/10.1200/jco.24.00110

Wang, W., Zhang, W., Su, L., Liu, L., Gao, Y., Wang, Q., Su, H., Song, Y., Zhang, H., Shen, J., Jing, H., Wang, S., Cen, X., Liu, H., Liu, A., Li, Z., Luo, J., He, J., Wang, J., … Zhou, D. (2024). Efficacy of chidamide maintenance therapy versus autologous stem cell transplantation versus observation as a post-remission choice in the survival of adult patients with peripheral T-cell lymphoma: Post hoc analysis of a prospective, multicenter, phase 2 study in China. Annals of Hematology, 103(8), 3061–3069. https://doi.org/10.1007/s00277-024-05708-w

Therapeutic Efficacy, Safety and Predictive Indicators of Eribulin Plus Anti-Angiogenic Medicine for Metastatic Breast Cancer. (2024). Journal of the College of Physicians and Surgeons Pakistan, 34(06), 682–687. https://doi.org/10.29271/jcpsp.2024.06.682

Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Baird, J. D., Brooks-Asplund, E., D’Silva, D., Kong, R., Mwatha, A., O’Keefe, K., Weetall, M., Spiegel, R., & Schwartz, G. K. (2024). Phase Ib Study of Unesbulin (PTC596) Plus Dacarbazine for the Treatment of Locally Recurrent, Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma. Journal of Clinical Oncology, 42(20), 2404–2414. https://doi.org/10.1200/jco.23.01684

Ryu Tiger, Y. K., Jain, S., Barta, S. K., Tolu, S., Estrella, B., Sawas, A., Lue, J. K., Francescone, M. M., Pro, B., & Amengual, J. E. (2024). Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma. Leukemia & Lymphoma, 65(6), 736–745. https://doi.org/10.1080/10428194.2024.2329996

Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, A. W., Solh, M., Hall, A. C., Alousi, A. M., Jamy, O. H., Perales, M.-A., Yao, J. M., … Holtan, S. G. (2023). Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis. New England Journal of Medicine, 388(25), 2338–2348. https://doi.org/10.1056/nejmoa2215943

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Paik, P. K., Luo, J., Ai, N., Kim, R., Ahn, L., Biswas, A., Coker, C., Ma, W., Wong, P., Buonocore, D. J., Lai, W. V., Chaft, J. E., Acharyya, S., Massagué, J., & Kris, M. G. (2022). Phase I trial of the TNF-α inhibitor certolizumab plus chemotherapy in stage IV lung adenocarcinomas. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-33719-6

Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471

Goldman, J. W., Piha-Paul, S. A., Curti, B., Pedersen, K. S., Bauer, T. M., Groenland, S. L., Carvajal, R. D., Chhaya, V., Kirby, G., McGlinchey, K., Hammond, S. A., Streicher, K., Townsley, D. M., Chae, Y. K., Voortman, J., Marabelle, A., & Powderly, J. (2022). Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors. Clinical Cancer Research, 28(17), 3709–3719. https://doi.org/10.1158/1078-0432.ccr-21-3016

Gamble, C. R., Chen, L., Szamreta, E., Monberg, M., Hershman, D., & Wright, J. (2022). Patterns of use and outcomes of adjuvant bevacizumab therapy prior to regulatory approval in women with newly diagnosed ovarian cancer. Archives of Gynecology and Obstetrics, 305(6), 1647–1654. https://doi.org/10.1007/s00404-021-06282-6

Moy, R. H., Greally, M., Chou, J. F., Li, J., Desai, A. M., Chalasani, S. B., Won, E., Kelsen, D. P., Ilson, D. H., Janjigian, Y. Y., Capanu, M., & Ku, G. Y. (2022). Phase I/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma. Cancer Chemotherapy and Pharmacology, 89(2), 255–265. https://doi.org/10.1007/s00280-021-04384-1

Safran, H. P., Winter, K., Ilson, D. H., Wigle, D., DiPetrillo, T., Haddock, M. G., Hong, T. S., Leichman, L. P., Rajdev, L., Resnick, M., Kachnic, L. A., Seaward, S., Mamon, H., Diaz Pardo, D. A., Anderson, C. M., Shen, X., Sharma, A. K., Katz, A. W., Salo, J., … Crane, C. H. (2022). Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. The Lancet Oncology, 23(2), 259–269. https://doi.org/10.1016/s1470-2045(21)00718-x

Powles, T., Yuen, K. C., Gillessen, S., Kadel, E. E., Rathkopf, D., Matsubara, N., Drake, C. G., Fizazi, K., Piulats, J. M., Wysocki, P. J., Buchschacher, G. L., Alekseev, B., Mellado, B., Karaszewska, B., Doss, J. F., Rasuo, G., Datye, A., Mariathasan, S., Williams, P., & Sweeney, C. J. (2022). Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. Nature Medicine, 28(1), 144–153. https://doi.org/10.1038/s41591-021-01600-6